Two Blood Thinners Added to Positive List, Now Available by Prescription Without Reimbursement
As of one week ago, the medication 'Clexane' (enoxaparin) and two other anticoagulant drugs have been added to the positive list. Patients can now obtain these medications from pharmacies with a specialist's prescription. Previously, these drugs were eligible for reimbursement from the Health Insurance Fund (FZOМ), but this is no longer the case. This change means that patients will now bear the full cost of these essential medications out-of-pocket. The inclusion of Clexane and the other two drugs on the positive list signifies a shift in how these treatments are accessed and funded. This development may impact patients who rely on these medications for managing conditions that cause blood clots. The specific details regarding the other two anticoagulant drugs added to the list have not been fully elaborated in the provided text. Patients are advised to consult with their specialists and pharmacists regarding the new prescription and reimbursement procedures.
This policy shift regarding anticoagulant medications represents a move towards cost-sharing between the state and patients. By transferring these drugs from a reimbursable to a non-reimbursable status on the positive list, the Health Insurance Fund aims to manage its budget. This decision may incentivize patients to explore more cost-effective alternatives if available, or it could place a significant financial burden on individuals requiring these treatments. Over the next decade, such adjustments in public health funding models will likely become more common as healthcare systems grapple with rising costs and demand, potentially leading to increased disparities in access based on socioeconomic status. The long-term impact on public health outcomes for conditions requiring anticoagulation will depend on patient adherence and the availability of affordable alternatives.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.